# Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors

> **NCT04060472** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Dong Wang** · enrollment: 57 (estimated)

## Conditions studied

- Advanced Hepatobiliary and Malignant Tumors

## Interventions

- **DRUG:** albumin-bound paclitaxel + oxaliplatin

## Key facts

- **NCT ID:** NCT04060472
- **Lead sponsor:** Dong Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-20
- **Primary completion:** 2021-04-20
- **Final completion:** 2023-10-20
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2019-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04060472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04060472, "Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04060472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*